L
Lyell Immunopharma D
D
LYEL
1.50000
USD
-0.12
(-7.41%)
Market Closed
Volume
71,172
EPS
0
Div Yield
0
P/E
-2
Market Cap
327,683,985
Novo Nordisk Surges in Profit and Sales
6 months ago
Stocks newsTitle: Lyell Immunopharma
Sector: Healthcare
Industry: Biotechnology
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.